Geode Capital Management
CNST

Geode Capital Management’s Constellation Pharmaceuticals, Inc. CNST Stock Holding History

Geode Capital Management’s Portfolio CNST Stock Details CNST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-611,273
Closed -$20.7M – 4931
2021
Q2 		$20.7M Buy
611,273
+49,428
+9% +$1.26M ﹤0.01% 1940
2021
Q1 		$13.1M Buy
561,845
+63,637
+13% +$1.93M ﹤0.01% 2163
2020
Q4 		$14.3M Buy
498,208
+41,204
+9% +$1.04M ﹤0.01% 1917
2020
Q3 		$9.26M Buy
457,004
+68,036
+17% +$1.66M ﹤0.01% 1990
2020
Q2 		$11.7M Buy
388,968
+103,179
+36% +$3.72M ﹤0.01% 1841
2020
Q1 		$8.98M Buy
285,789
+59,462
+26% +$2.07M ﹤0.01% 1793
2019
Q4 		$10.7M Buy
226,327
+118,009
+109% +$3.41M ﹤0.01% 1968
2019
Q3 		$699K Buy
108,318
+3,084
+3% +$25.8K ﹤0.01% 3360
2019
Q2 		$1.29M Buy
105,234
+15,647
+17% +$174K ﹤0.01% 3153
2019
Q1 		$1.21M Buy
89,587
+75,852
+552% +$680K ﹤0.01% 3081
2018
Q4 		$55K Buy
13,735
+1,987
+17% +$12K ﹤0.01% 3975
2018
Q3 		$79K Buy
+11,748
New +$112K ﹤0.01% 3973

Geode Capital Management's CNST Position: Q3 2021 in Review

Geode Capital Management sold out of Constellation Pharmaceuticals, Inc. (CNST) in Q3 2021, closing a stake of 611,273 shares — an estimated $20.7M sold.

Geode Capital Management first reported a position in CNST in Q3 2018 and held it in 12 quarters. The position peaked at $20.7M in Q2 2021. 0 funds tracked by Wall St. Rank hold CNST as of Q3 2021.

  • Geode Capital Management reported no remaining Constellation Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Geode Capital Management sold 611,273 Constellation Pharmaceuticals, Inc. shares in Q3 2021, an estimated $20.7M.
  • Geode Capital Management first reported a position in Constellation Pharmaceuticals, Inc. in Q3 2018 and held it in 12 quarters.
  • Geode Capital Management's Constellation Pharmaceuticals, Inc. position peaked at $20.7M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Constellation Pharmaceuticals, Inc. as of Q3 2021.

Based on Geode Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.